{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:38:14Z","timestamp":1793194694535,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK44442"],"award-info":[{"award-number":["DK44442"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK58379"],"award-info":[{"award-number":["DK58379"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Liver Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.livres.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T18:51:24Z","timestamp":1737226284000},"page":"94-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["New drug therapies for metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9360-7650","authenticated-orcid":false,"given":"John Y.L.","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.livres.2025.01.001_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2020.10.030","article-title":"Hepatokines and adipokines in NASH-related hepatocellular carcinoma","volume":"74","author":"Kucukoglu","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.livres.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","article-title":"Bile acid metabolism and signaling in liver disease and therapy","volume":"1","author":"Chiang","year":"2017","journal-title":"Liver Res"},{"key":"10.1016\/j.livres.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-nutr-082018-124344","article-title":"Bile acids as metabolic regulators and nutrient sensors","volume":"39","author":"Chiang","year":"2019","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.livres.2025.01.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.livres.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.livres.2020.05.001","article-title":"Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis","volume":"4","author":"Chiang","year":"2020","journal-title":"Liver Res"},{"key":"10.1016\/j.livres.2025.01.001_bib9","series-title":"Pathobiology of Human Disease","first-page":"1770","article-title":"Liver physiology: metabolism and detoxification","author":"Chiang","year":"2014"},{"key":"10.1016\/j.livres.2025.01.001_bib10","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.livres.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","article-title":"Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice","volume":"64","author":"Xu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.livres.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","article-title":"Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.livres.2025.01.001_bib17","doi-asserted-by":"crossref","first-page":"83951","DOI":"10.18632\/oncotarget.13796","article-title":"Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis","volume":"7","author":"Gong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.livres.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/hep4.1263","article-title":"Role of farnesoid X receptor and bile acids in hepatic tumor development","volume":"2","author":"Takahashi","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.livres.2025.01.001_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00070-16","article-title":"Farnesoid X receptor signaling shapes the gut microbiota and controls hepatic lipid metabolism","volume":"1","author":"Zhang","year":"2016","journal-title":"mSystems"},{"key":"10.1016\/j.livres.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0016-5085(95)90083-7","article-title":"Failure of intravenous infusion of taurocholate to down-regulate cholesterol 7 alpha-hydroxylase in rats with biliary fistulas","volume":"108","author":"Pandak","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.livres.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.livres.2025.01.001_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.livres.2025.01.001_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.livres.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2025.01.001_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2025.01.001_bib29","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbalip.2019.07.006","article-title":"Ursodeoxycholic acid is a GPBAR1 agonist and resets liver\/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH","volume":"1864","author":"Carino","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.livres.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.23032","article-title":"The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders","volume":"50","author":"Keitel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1669940","article-title":"Role of TGR5 (GPBAR1) in liver disease","volume":"38","author":"Keitel","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.livres.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","article-title":"Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism","volume":"292","author":"Pathak","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.livres.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.livres.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2009.08.001","article-title":"Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders","volume":"30","author":"Fiorucci","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.livres.2025.01.001_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.609060","article-title":"TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation","volume":"11","author":"Shi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.livres.2025.01.001_bib38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-8587(16)30155-3","article-title":"Clinical relevance of the bile acid receptor TGR5 in metabolism","volume":"5","author":"van Nierop","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.livres.2025.01.001_bib39","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.bbadis.2017.08.021","article-title":"Bile acid receptors in the biliary tree: TGR5 in physiology and disease","volume":"1864","author":"Deutschmann","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.livres.2025.01.001_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/164_2019_230","article-title":"Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors","volume":"256","author":"Keitel","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.livres.2025.01.001_bib41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/gutjnl-2021-326541","article-title":"6\u03b1-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice","volume":"72","author":"Makki","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.livres.2025.01.001_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.livres.2025.01.001_bib43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.livres.2025.01.001_bib44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/gutjnl-2015-309871","article-title":"TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice","volume":"66","author":"McGavigan","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.livres.2025.01.001_bib45","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/cells8111467","article-title":"The G protein-coupled bile acid receptor TGR5 (Gpbar1) modulates endothelin-1 signaling in liver","volume":"8","author":"Klindt","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.livres.2025.01.001_bib46","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/nu12092598","article-title":"TGR5 signaling in hepatic metabolic health","volume":"12","author":"Holter","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.livres.2025.01.001_bib47","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cmet.2021.04.009","article-title":"Hypothalamic bile acid-TGR5 signaling protects from obesity","volume":"33","author":"Castellanos-Jankiewicz","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","article-title":"Central nervous system control of food intake","volume":"404","author":"Schwartz","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.livres.2025.01.001_bib49","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s42255-022-00611-y","article-title":"Acts of appetite: neural circuits governing the appetitive, consummatory, and terminating phases of feeding","volume":"4","author":"Alcantara","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib50","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s12276-022-00758-4","article-title":"Brain circuits for promoting homeostatic and non-homeostatic appetites","volume":"54","author":"Ahn","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.livres.2025.01.001_bib51","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1469-0691.12140","article-title":"Gut microbiota and non-alcoholic fatty liver disease: new insights","volume":"19","author":"Aron-Wisnewsky","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.livres.2025.01.001_bib52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/MOG.0000000000000039","article-title":"The gut microbiota and the metabolic health of the host","volume":"30","author":"Joyce","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.livres.2025.01.001_bib53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib54","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1042\/CS20230812","article-title":"Gut microbiota depletion aggravates bile acid-induced liver pathology in mice with a human-like bile acid composition","volume":"137","author":"Verkade","year":"2023","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.livres.2025.01.001_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2025.01.001_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.livres.2025.01.001_bib57","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.livres.2025.01.001_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature11225","article-title":"Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-\/- mice","volume":"487","author":"Devkota","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.livres.2025.01.001_bib59","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/dbi17-0007","article-title":"Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery","volume":"67","author":"Bozadjieva","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.livres.2025.01.001_bib60","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib61","doi-asserted-by":"crossref","first-page":"E446","DOI":"10.1152\/ajpendo.00140.2019","article-title":"Akkermansia muciniphila abundance is lower in severe obesity, but its increased level after bariatric surgery is not associated with metabolic health improvement","volume":"317","author":"Dao","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib62","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2018.11.017","article-title":"Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery","volume":"156","author":"Albaugh","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2025.01.001_bib63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","article-title":"FXR is a molecular target for the effects of vertical sleeve gastrectomy","volume":"509","author":"Ryan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.livres.2025.01.001_bib64","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.soard.2017.05.024","article-title":"Bile acid profiles over 5 years after gastric bypass and duodenal switch: results from a randomized clinical trial","volume":"13","author":"Risstad","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.livres.2025.01.001_bib65","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOG.0000000000000057","article-title":"Bile acids and the gut microbiome","volume":"30","author":"Ridlon","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.livres.2025.01.001_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1888673","article-title":"Links between gut microbiome composition and fatty liver disease in a large population sample","volume":"13","author":"Ruuskanen","year":"2021","journal-title":"Gut Microbes"},{"key":"10.1016\/j.livres.2025.01.001_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.livres.2025.01.001_bib69","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41467-021-21744-w","article-title":"Hyocholic acid species as novel biomarkers for metabolic disorders","volume":"12","author":"Zheng","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.livres.2025.01.001_bib70","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.chom.2020.12.004","article-title":"A microbial metabolite remodels the gut-liver axis following bariatric surgery","volume":"29","author":"Chaudhari","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.livres.2025.01.001_bib71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41589-020-0604-z","article-title":"Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects","volume":"17","author":"Chaudhari","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.livres.2025.01.001_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.livres.2025.01.001_bib73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cld.861","article-title":"Bile acid biology, pathophysiology, and therapeutics","volume":"15","author":"Chiang","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.livres.2025.01.001_bib74","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.livres.2025.01.001_bib75","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2025.01.001_bib76","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2025.01.001_bib77","first-page":"158","article-title":"Cholestatic pruritus: a retrospective analysis on clinical characteristics and treatment response","volume":"11","author":"Huesmann","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.livres.2025.01.001_bib78","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.livres.2025.01.001_bib79","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1124\/jpet.123.001900","article-title":"Development of cilofexor, an intestinally-biased farnesoid X receptor agonist, for the treatment of fatty liver disease","volume":"389","author":"Hollenback","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.livres.2025.01.001_bib81","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib82","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/apt.15967","article-title":"Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea","volume":"52","author":"Camilleri","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.livres.2025.01.001_bib83","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib84","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib85","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2025.01.001_bib86","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.livres.2025.01.001_bib87","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2025.01.001_bib88","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","article-title":"FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response","volume":"106","author":"Potthoff","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.livres.2025.01.001_bib89","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3249","article-title":"FGF21 regulates metabolism and circadian behavior by acting on the nervous system","volume":"19","author":"Bookout","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2025.01.001_bib90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib91","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib92","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.livres.2025.01.001_bib94","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.livres.2025.01.001_bib95","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib96","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13543784.2020.1708899","article-title":"Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.livres.2025.01.001_bib97","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1073\/pnas.1633737100","article-title":"Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability","volume":"100","author":"Grover","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.livres.2025.01.001_bib98","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.livres.2025.01.001_bib99","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cmet.2011.11.010","article-title":"Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia","volume":"15","author":"Haeusler","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib100","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/s41401-024-01303-x","article-title":"A new mechanism of thyroid hormone receptor \u03b2 agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.livres.2025.01.001_bib101","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2025.01.001_bib102","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.livres.2025.01.001_bib103","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2025.01.001_bib104","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.livres.2025.01.001_bib106","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.livres.2025.01.001_bib107","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.livres.2025.01.001_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.livres.2025.01.001_bib109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.livres.2025.01.001_bib110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib111","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.livres.2025.01.001_bib112","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.livres.2025.01.001_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib114","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.livres.2025.01.001_bib115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib116","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib119","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.livres.2025.01.001_bib120","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib121","doi-asserted-by":"crossref","first-page":"7784","DOI":"10.3390\/ijms25147784","article-title":"The GLP-1 receptor agonist liraglutide decreases primary bile acids and serotonin in the colon independently of feeding in mice","volume":"25","author":"Nonogaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.livres.2025.01.001_bib122","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2025.01.001_bib123","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.livres.2025.01.001_bib124","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.livres.2025.01.001_bib125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/bip.22072","article-title":"Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents","volume":"98","author":"Day","year":"2012","journal-title":"Biopolymers"},{"key":"10.1016\/j.livres.2025.01.001_bib126","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ando.2022.12.423","article-title":"Dual GIP\/GLP-1 receptor agonists: new advances for treating type-2 diabetes","volume":"84","author":"Scheen","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.livres.2025.01.001_bib127","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","article-title":"Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study","volume":"62","author":"Bergmann","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.livres.2025.01.001_bib128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.livres.2025.01.001_bib129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/apt.18042","article-title":"Randomised clinical trial: design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures","volume":"60","author":"Vuppalanchi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.livres.2025.01.001_bib130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.livres.2025.01.001_bib131","article-title":"A new drug for obesity: tirzepatide","author":"Sidhu","year":"202525267","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.livres.2025.01.001_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1402583","article-title":"Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence","volume":"15","author":"Corrao","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.livres.2025.01.001_bib133","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.livres.2025.01.001_bib134","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and efficacy of novel incretin co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2025.01.001_bib135","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.cell.2024.02.019","article-title":"The underappreciated diversity of bile acid modifications","volume":"187","author":"Mohanty","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.livres.2025.01.001_bib136","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control TH17 and Treg cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.livres.2025.01.001_bib137","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmet.2020.11.017","article-title":"Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism","volume":"33","author":"Zheng","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2025.01.001_bib138","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-021-03832-5","article-title":"Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians","volume":"599","author":"Sato","year":"2021","journal-title":"Nature"}],"container-title":["Liver Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568425000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568425000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T17:43:43Z","timestamp":1750959823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542568425000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":138,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2542568425000017"],"URL":"https:\/\/doi.org\/10.1016\/j.livres.2025.01.001","relation":{},"ISSN":["2542-5684"],"issn-type":[{"value":"2542-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drug therapies for metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Liver Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.livres.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co. Ltd\u00e9","name":"copyright","label":"Copyright"}]}}